Finance

Beta
Lists
OLMA:NASDAQ
Olema Pharmaceuticals Inc
$10.53
+5.30%
(+0.53) 1D
$10.61
+0.76% (+0.080)
Pre-market
Closed: Jun 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OLMA...
Open
$9.99
High
$11.01
Low
$9.89
Mkt. cap
919.77M
Avg. vol.
1.50M
Volume
2.21K
52-wk high
$36.26
52-wk low
$4.12
EPS
-$2.03
Beta
1.98
Shares outstanding
87.35M
No. of employees
137
Open
$9.99
High
$11.01
Low
$9.89
Mkt. cap
919.77M
Avg. vol.
1.50M
Volume
2.21K
52-wk high
$36.26
52-wk low
$4.12
EPS
-$2.03
Beta
1.98
Shares outstanding
87.35M
No. of employees
137
News stories
From sources across the web
About Olema Pharmaceuticals Inc
CEO-
Employees137
Founded2006
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websiteolema.com
Analyst Ratings
Based on 10 analysts giving stock ratings to OLMA in the past 3 months
Strong Buy
Buy
9
Hold
1
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for OLMA in the last 3 months.
Highest
Current $10.53
$62.00 (+488.79%)
Average
$38.14 (+262.20%)
Lowest
$23.00 (+118.42%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
06/09/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$24.00
+127.9%
06/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$38.00
+260.9%
06/03/2026
Michael Yee
UBS
Buy
Maintained
$45.00
+327.4%
06/02/2026
Bradley Canino
Guggenheim
Buy
Maintained
$35.00
+232.4%
06/01/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$62.00
+488.8%
05/31/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$23.00
+118.4%
05/12/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$48.00
+355.8%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$40.00
+279.9%
04/20/2026
Kalpit Patel
Wolfe Research
Hold
Initiated
-
-
03/26/2026
Dennis Ding
Jefferies
Buy
Initiated
$40.00
+279.9%
03/19/2026
Laura Prendergast
Stifel Nicolaus
Buy
Initiated
$48.00
+355.8%
02/11/2026
Last report
May 12, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.52 / -$0.54
+3.51%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
33.90M
39.95M
43.22M
49.23M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.96M
5.93M
6.86M
8.75M
Operating expense
37.86M
45.88M
50.08M
57.99M
Total operating expenses
37.86M
45.88M
50.08M
57.99M
Operating income
-37.86M
-45.88M
-50.08M
-57.99M
Other non operating income
38.00K
12.00K
13.00K
121.00K
EBT including unusual items
-43.78M
-42.22M
-46.06M
-53.09M
EBT excluding unusual items
-33.78M
-42.22M
-46.06M
-53.09M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-43.78M
-42.22M
-46.06M
-53.09M
Net profit margin
-
-
-
-
Earnings per share
-0.51
-0.49
-0.50
-0.52
Interest and investment income
4.04M
3.65M
4.01M
4.78M
Interest expense
-
-
-
-
Net interest expenses
4.04M
3.65M
4.01M
4.78M
Depreciation and amortization charges
-
-
-
-
EBITDA
-37.73M
-45.83M
-49.90M
-57.87M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer